Linnaeus Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$6.07M
- Investors
-
7
Linnaeus Therapeutics General Information
Description
Developer of molecular therapeutics designed to treat cancer and skin pigmentation disorders. The company's therapeutics utilize small-molecule agents to increase or decrease the amount of melanin pigment produced by skin cells, enabling medical practitioners to treat cancer and skin pigmentation disorders due to oncogenic mutations effectively.
Contact Information
Website
linnaeustx.comCorporate Office
- 30 Washington Avenue
- Suite F
- Haddonfield, NJ 08033
- United States
Corporate Office
- 30 Washington Avenue
- Suite F
- Haddonfield, NJ 08033
- United States
Linnaeus Therapeutics Timeline
Linnaeus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Later Stage VC (Series B) | 02-Apr-2026 | $6.07M | Completed | Clinical Trials - Phase 2 | ||
| 15. Grant | 26-Mar-2025 | Completed | Clinical Trials - Phase 2 | |||
| 14. Later Stage VC (Series B) | 23-Dec-2024 | Completed | Clinical Trials - Phase 2 | |||
| 13. Later Stage VC (Series B) | 26-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 12. Accelerator/Incubator | 01-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 11. Grant | 06-Apr-2022 | Completed | Clinical Trials - Phase 1 | |||
| 10. Later Stage VC (Series B) | 24-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 9. Early Stage VC (Series B) | 17-Sep-2019 | Completed | Product Development | |||
| 8. Early Stage VC (Series A2) | 07-Feb-2019 | $2.16M | $4.32M | Completed | Product Development | |
| 7. Early Stage VC (Series A1) | 07-Sep-2018 | $2.16M | $2.16M | Completed | Startup |
Linnaeus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B7 | ||||||||
| Series B6 | ||||||||
| Series B5 | ||||||||
| Series B4 | ||||||||
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A2 | 1,491,610 | $0.000100 | $1.45 | $1.45 | 1x | $1.45 | 7.18% | |
| Series A1 | 2,193,562 | $0.000100 | $0.98 | $0.98 | 1x | $0.98 | 10.56% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Linnaeus Therapeutics Comparisons
Industry
Financing
Details
Linnaeus Therapeutics Competitors (99)
One of Linnaeus Therapeutics’s 99 competitors is Accent Therapeutics, a Venture Capital-Backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Accent Therapeutics | Venture Capital-Backed | Lexington, MA | ||||
| MaveriX Oncology | Venture Capital-Backed | Palo Alto, CA | ||||
| Equillium | Formerly VC-backed | La Jolla, CA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Gylden Pharma | Venture Capital-Backed | Abingdon, United Kingdom |
Linnaeus Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Linnaeus Therapeutics Patents
Linnaeus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022275860-A1 | Diagnostic methods and compositions for treatment of cancer | Pending | 19-May-2021 | ||
| CA-3219305-A1 | Diagnostic methods and compositions for treatment of cancer | Pending | 19-May-2021 | ||
| EP-4341695-A2 | Diagnostic methods and compositions for treatment of cancer | Pending | 19-May-2021 | ||
| EP-4341695-A4 | Diagnostic methods and compositions for treatment of cancer | Pending | 19-May-2021 | ||
| US-20240245674-A1 | Diagnostic methods and compositions for treatment of cancer | Pending | 19-May-2021 | A61K31/473 |
Linnaeus Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Linnaeus Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Springboard Enterprises | Accelerator/Incubator | |||
| National Cancer Institute | Government | |||
| Kairos Ventures | Venture Capital | Minority | ||
| Penn Medicine Co-Investment Program | Venture Capital | Minority | ||
| National Institute for Allergy and Infectious Disease | Government |
Linnaeus Therapeutics FAQs
-
When was Linnaeus Therapeutics founded?
Linnaeus Therapeutics was founded in 2016.
-
Where is Linnaeus Therapeutics headquartered?
Linnaeus Therapeutics is headquartered in Haddonfield, NJ.
-
What is the size of Linnaeus Therapeutics?
Linnaeus Therapeutics has 5 total employees.
-
What industry is Linnaeus Therapeutics in?
Linnaeus Therapeutics’s primary industry is Drug Discovery.
-
Is Linnaeus Therapeutics a private or public company?
Linnaeus Therapeutics is a Private company.
-
What is the current valuation of Linnaeus Therapeutics?
The current valuation of Linnaeus Therapeutics is .
-
What is Linnaeus Therapeutics’s current revenue?
The current revenue for Linnaeus Therapeutics is .
-
How much funding has Linnaeus Therapeutics raised over time?
Linnaeus Therapeutics has raised $35.6M.
-
Who are Linnaeus Therapeutics’s investors?
Springboard Enterprises, National Cancer Institute, Kairos Ventures, Penn Medicine Co-Investment Program, and National Institute for Allergy and Infectious Disease are 5 of 7 investors who have invested in Linnaeus Therapeutics.
-
Who are Linnaeus Therapeutics’s competitors?
Accent Therapeutics, MaveriX Oncology, Equillium, Centrose, and Gylden Pharma are some of the 99 competitors of Linnaeus Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
